In recent years, the field of oncology has witnessed significant advancements, particularly in immunotherapy. Among the various treatment options available, Opdivo and Yervoy have emerged as two prominent therapies for several types of cancer. Both drugs are designed to harness the body’s immune system to fight cancer cells, but they operate through different mechanisms and are often used in conjunction with one another. Opdivo, known generically as nivolumab, is a monoclonal antibody that blocks a protein called PD-1, which cancer cells exploit to evade detection by the immune system. By inhibiting PD-1, Opdivo enhances the ability of T-cells to recognize and attack cancer cells. On the other hand, Yervoy, or…